Dossier assessment
Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V
Report documents
-
Extract of dossier assessment
Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V
-
Dossierbewertung
Daridorexant (chronic insomnia) - Benefit assessment according to § 35a SGB V
Dossier assessment
Adults with insomnia, characterized by symptoms present for at least 3 months, who have not responded to cognitive behavioural therapy or for whom this type of therapy is not suitable or not feasible
Added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2023-05-12 A G-BA decision was published.
Project details
- Project no.
- A22-123
- Commission
- Commission awarded on 16.11.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
Connected Projects
-
Dossier assessment
Daridorexant (insomnia) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed